```html

Zaïri’s Disease (Zaire ebolavirus Infection) – Complete Medical Guide

Overview

Zaire ebolavirus, the most lethal species of the Ebolavirus genus, causes a severe and often fatal illness commonly referred to as Zaïri’s disease or simply “Ebola virus disease (EVD).” First identified during the 1976 outbreak in what was then Zaire (now the Democratic Republic of the Congo, DRC), this virus has since caused several major epidemics, most notably the 2014‑2016 West Africa outbreak that resulted in >28,000 cases and 11,000 deaths.<sup>[1]</sup>

The disease is zoonotic—meaning it originates in animals—primarily fruit bats (Rousettus spp.) and can spread to humans through direct contact with infected animal tissue or later, via human‑to‑human transmission through blood, bodily fluids, or contaminated objects. While anyone can be infected, the highest risk groups are health‑care workers, family members caring for sick patients, and people who handle wild game or bushmeat in endemic regions.<sup>[2]</sup>

According to the World Health Organization (WHO), Zaire ebolavirus remains the most common cause of Ebola outbreaks, accounting for >95 % of recorded cases since 2000.<sup>[3]</sup> In 2022, there were 5 confirmed outbreaks worldwide, with a cumulative case‑fatality ratio (CFR) ranging from 30 % to 90 %, depending on the timeliness of care and availability of therapeutics.<sup>[4]</sup>

Symptoms

The incubation period is typically 2–21 days (average 8–10 days). Early signs are non‑specific and can be mistaken for malaria or influenza, which contributes to delayed diagnosis. The full clinical picture usually follows a three‑phase pattern:

• Phase 1 – Early (Days 1‑5): fever, intense fatigue, muscle aches, headache, sore throat, and loss of appetite.
• Phase 2 – Acute (Days 5‑10): worsening fever, vomiting, diarrhea, abdominal pain, and a distinctive maculopapular rash that may spread over the trunk and limbs.
• Phase 3 – Complicated (Days 10‑14+): hemorrhagic manifestations (e.g., bleeding gums, conjunctival hemorrhage, petechiae, ecchymoses), organ dysfunction, shock, and multi‑organ failure.

Below is a more detailed symptom checklist:

Symptom	Typical Onset	Clinical Description
Fever ≥38 °C (100.4 °F)	Day 1‑2	Sudden, high‑grade, often accompanied by chills.
Headache	Day 1‑3	Often severe, dull‑throbbing.
Myalgia (muscle aches)	Day 2‑4	Generalized, may limit movement.
Fatigue/Weakness	Day 1‑5	Profound, not relieved by rest.
Sore throat	Day 2‑4	Dry, may progress to dysphagia.
Loss of appetite	Day 2‑5	Often leads to rapid weight loss.
Rash	Day 5‑7	Maculopapular, starts on trunk, spreads to extremities.
Nausea & vomiting	Day 5‑9	Can be projectile; vomiting blood may occur.
Diarrhea (often watery)	Day 5‑9	May be bloody; contributes to dehydration.
Abdominal pain	Day 5‑9	Cramping, can mimic appendicitis.
Conjunctival injection	Day 6‑10	Redness of eyes without discharge.
Bleeding gums, nosebleeds	Day 7‑12	Indicative of coagulopathy.
Petechiae & ecchymoses	Day 8‑14	Small red or purple spots on skin.
Hematochezia (blood in stool)	Day 9‑14	Dark/red stools, may be “tarry.”
Hepatic & renal dysfunction	Day 10‑14	Elevated transaminases, rising creatinine.
Shock (hypotension, tachycardia)	Day 10‑14	Requires urgent resuscitation.

Because early symptoms overlap with many common infections, any unexplained fever in a person who has been in an endemic area or had contact with a suspected case should prompt immediate medical evaluation.

Causes and Risk Factors

What causes Zaïri’s disease?

Zaire ebolavirus is an enveloped, single‑stranded, negative‑sense RNA virus belonging to the family Filoviridae. The virus gains entry to host cells via the glycoprotein (GP) that binds to cell‑surface receptors such as NPC1. Once inside, it hijacks the host’s transcription machinery, producing large amounts of viral particles that lead to widespread endothelial damage, immune dysregulation, and coagulopathy.<sup>[5]</sup>

Key risk factors

• Geographic exposure: Living in or traveling to regions with documented Zaire ebolavirus circulation (DRC, Uganda, South Sudan, Guinea, Sierra Leone, Liberia).
• Occupational exposure: Healthcare workers, laboratory personnel, hunters, and bushmeat vendors.
• Close contact with infected individuals: Caring for a sick family member, performing burial rituals, or sharing personal items (clothing, bedding).
• Inadequate infection‑control practices: Lack of personal protective equipment (PPE), improper needle handling, or unsafe injection practices.
• Underlying health conditions: Immunosuppression, malnutrition, or chronic liver disease may increase susceptibility to severe disease.

Diagnosis

A confirmed diagnosis requires laboratory testing because clinical presentation alone is insufficient.

Specimen collection

• Blood (serum or plasma) is the preferred specimen for acute infection.
• Other fluids—urine, saliva, stool, or cerebrospinal fluid—can be useful in later stages.
• All specimens must be collected with strict biosafety level‑4 (BSL‑4) precautions.

Laboratory tests

1. Real‑time reverse transcription polymerase chain reaction (RT‑PCR): Gold‑standard, detects viral RNA within 3–10 days of symptom onset. Sensitivity >95 %.
2. Antigen‑capture enzyme‑linked immunosorbent assay (ELISA): Detects viral proteins; useful when PCR capacity is limited.
3. Serology (IgM/IgG ELISA, immunofluorescence): Indicates recent or past infection; not reliable for early diagnosis.
4. Virus isolation (cell culture): Performed only in high‑containment labs; mainly for research.

Additional supportive tests

Given the risk of multi‑organ involvement, clinicians order complete blood counts, liver function tests, renal panel, coagulation profile, and electrolytes to guide treatment and monitor complications.

Treatment Options

There is no single “cure,” but advances in therapeutics have dramatically reduced mortality when administered early.

Antiviral therapies (approved or under emergency use)

• Inmazeb (atoltivimab, maftivimab, odesivimab‑betadex): A triple‑monoclonal antibody cocktail approved by the U.S. FDA (2020) for Zaire ebolavirus infection. Clinical trials showed a 28‑day mortality reduction from 49 % to 18 % when given within 5 days of symptom onset.<sup>[6]</sup>
• Ebanga (ansuvimab‑zykl): Single‑dose monoclonal antibody also FDA‑approved (2020); similar efficacy to Inmazeb in randomized studies.
• Remdesivir: Broad‑spectrum antiviral with limited data; may be considered when monoclonal antibodies are unavailable.

Supportive care (the cornerstone of management)

1. Fluid resuscitation with balanced crystalloids to correct dehydration and maintain perfusion.
2. Electrolyte replacement (potassium, magnesium) guided by daily labs.
3. Vasopressor support for refractory hypotension.
4. Broad‑spectrum antibiotics only if bacterial superinfection is suspected.
5. Transfusion of plasma or platelets for severe coagulopathy, following WHO guidelines.
6. Renal replacement therapy for acute kidney injury, when indicated.

Procedural interventions

• Mechanical ventilation for respiratory failure.
• Intracranial pressure monitoring if encephalitis or cerebral edema occurs.

Lifestyle & supportive measures

While hospitalized, patients benefit from psychosocial support, nutritional supplementation (high‑protein oral or enteral feeds), and careful skin care to prevent pressure ulcers.

Living with Zaïri’s disease (Zaire ebolavirus infection)

Survivors often face long‑term sequelae that require multidisciplinary follow‑up.

Post‑recovery monitoring

• Ophthalmology: Uveitis and vision loss can appear months after discharge; annual eye exams are advised.
• Neurological assessment: Memory deficits, depression, and peripheral neuropathy are reported in up to 30 % of survivors.<sup>[7]</sup>
• Musculoskeletal health: Joint pain and arthralgia may persist; gentle physiotherapy helps restore range of motion.
• Reproductive health: Women who were pregnant during infection should receive obstetric follow‑up; viral RNA has been detected in semen for up to 9 months, so safe‑sex practices are recommended.

Daily management tips for survivors

1. Maintain a balanced diet rich in protein, vitamins A, C, and zinc to support immune recovery.
2. Stay hydrated; aim for at least 2 L of fluid per day unless contraindicated.
3. Engage in low‑impact exercise (walking, stretching) as tolerated to rebuild stamina.
4. Track any new symptoms (e.g., eye redness, headaches, joint swelling) and report them promptly.
5. Adhere to vaccination schedules; several experimental Ebola vaccines (e.g., rVSV‑ZEBOV) have demonstrated >90 % efficacy and are offered in endemic areas.
6. Seek mental‑health support; PTSD and anxiety are common after severe infectious outbreaks.

Prevention

Because there is no cure for Ebola, prevention focuses on breaking the chain of transmission.

Vaccination

• rVSV‑ZEBOV (ERVEBO): Live‑attenuated recombinant vesicular stomatitis virus vaccine. Licensed by the EMA and FDA; a single dose confers >97 % protection for at least 12 months.<sup>[8]</sup>
• Ad26.ZEBOV/MVA‑BN‑Filo: Two‑dose regimen used in ring‑vaccination strategies.

Personal protective measures

• Wear appropriate PPE (gloves, fluid‑impermeable gown, goggles, N95/FFP2 respirator) when caring for suspected patients.
• Practice strict hand hygiene: wash with soap or use an alcohol‑based sanitizer (>60 % ethanol) for at least 20 seconds.
• Avoid contact with wildlife (especially fruit bats, non‑human primates) and refrain from hunting or butchering them.
• Cook meat thoroughly (boiling for ≥10 minutes) to inactivate the virus.
• Use safe burial practices: trained teams should handle bodies with PPE, and families should be educated about the risks.

Community‑level interventions

• Rapid case identification and contact tracing (aim for isolation within 48 hours of symptom onset).
• Establishment of Ebola Treatment Units (ETUs) with proper waste‑management systems.
• Public‑health education campaigns that dispel myths and promote early presentation to health facilities.

Complications

If not recognized and managed promptly, Zaïri’s disease can progress to life‑threatening complications:

• Severe hemorrhage: Due to disseminated intravascular coagulation (DIC) leading to gastrointestinal, pulmonary, or intracranial bleeding.
• Multi‑organ failure: Acute liver injury (ALT/AST >10× ULN), acute kidney injury (creatinine rise >2 mg/dL), and cardiac dysfunction.
• Shock and cardiovascular collapse: Often refractory to fluids alone; requires vasopressors.
• Neurologic sequelae: Encephalitis, seizures, or long‑term cognitive deficits.
• Secondary infections: Bacterial translocation from a compromised gut barrier can cause sepsis.
• Persistent viral reservoirs: Detectable virus in semen, ocular fluid, or cerebrospinal fluid months after recovery, posing transmission risk.

When to Seek Emergency Care

---

References:
<sup>[1]</sup> World Health Organization. “Ebola Situation Report – 2016.” WHO, 2016.
<sup>[2]</sup> CDC. “Ebola (Zaire) Virus Disease – Transmission.” Centers for Disease Control and Prevention, 2023.
<sup>[3]</sup> WHO. “Ebola Virus Disease – Data & Statistics.” World Health Organization, 2022.
<sup>[4]</sup> OCHA. “Ebola Outbreaks 2022 Overview.” United Nations Office for the Coordination of Humanitarian Affairs, 2023.
<sup>[5]</sup> Feldmann H, Geisbert TW. “Ebola haemorrhagic fever.” N Engl J Med. 2011;364:377‑387.
<sup>[6]</sup> Mulangu S et al. “A Randomized, Controlled Trial of ZMapp for Ebola Virus Disease.” N Engl J Med. 2019.
<sup>[7]</sup> Schieffelin JS et al. “Long-Term Sequelae in Ebola Survivors.” Lancet Infect Dis. 2020.
<sup>[8]</sup> Henao‑Restrepo AM et al. “Efficacy and Effectiveness of the rVSV‑ZEBOV Vaccine.” Vaccine. 2022.

```